Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Gastrointestinal Stromal Tumors
  • Phenylurea Compounds
  • Pyridines

abstract

  • Regorafenib has significant activity in patients with advanced GIST after failure of both imatinib and sunitinib. A phase III trial of regorafenib versus placebo is ongoing to define more fully the safety and efficacy of regorafenib in this setting.

publication date

  • July 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3675695

Digital Object Identifier (DOI)

  • 10.1200/JCO.2011.39.9394

PubMed ID

  • 22614970

Additional Document Info

start page

  • 2401

end page

  • 7

volume

  • 30

number

  • 19